Regeneron Pharmaceuticals, Inc. (REGN) Confident on Odronextamab Approval After Setbacks

We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Regeneron Pharmaceuticals, Inc. is one of them.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) tops our list for being one of the cheap biotech stocks to buy. It is a biotechnology company developing treatments for serious diseases, including eye conditions, inflammatory disorders, cancer, and rare diseases. Its strong R&D and antibody platform support long-term growth from drugs like Dupixent and new launches in oncology and respiratory care.

In Q2 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported strong results driven by Dupixent, which generated $4.34 billion in sales, exceeding expectations. However, Eylea sales declined 25%, and the FDA again declined approval for the blood cancer therapy odronextamab due to manufacturing issues at a third-party facility. The business remains confident that these issues can be resolved, as the drug is already approved in Europe and targets follicular lymphoma.

The company continues to emphasize innovation, awarding its 13th annual Regeneron Prize for Creative Innovation to early-career biomedical researchers and supporting global STEM education initiatives.

Regeneron Pharmaceuticals, Inc. (REGN) Confident on Odronextamab Approval After Setbacks

Looking ahead, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s priorities include resolving regulatory challenges for odronextamab, expanding Dupixent’s market, and advancing new oncology and respiratory launches to sustain growth despite near-term setbacks.

While we acknowledge the risk and potential of REGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than REGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.